2012
DOI: 10.1371/journal.pone.0049566
|View full text |Cite
|
Sign up to set email alerts
|

Ezrin Interacts with the SARS Coronavirus Spike Protein and Restrains Infection at the Entry Stage

Abstract: BackgroundEntry of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and its envelope fusion with host cell membrane are controlled by a series of complex molecular mechanisms, largely dependent on the viral envelope glycoprotein Spike (S). There are still many unknowns on the implication of cellular factors that regulate the entry process.Methodology/Principal FindingsWe performed a yeast two-hybrid screen using as bait the carboxy-terminal endodomain of S, which faces the cytosol during and after open… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
50
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
4
4

Relationship

1
7

Authors

Journals

citations
Cited by 52 publications
(51 citation statements)
references
References 69 publications
(107 reference statements)
1
50
0
Order By: Relevance
“…A WO patent [78] and a Canadian patent [79] as well as their paper [80] published by inventors from Hong-Kong Pasteur Research Center, China, relates to the identification and/ or use of anti-CoV molecules that inhibit or disrupt viral protein-cellular protein interactions, important or essential in the viral life cycle of a CoV, for example, a method for identifying inhibitors of early stages of SARS-CoV replication cycle by using lentiviral Spike pseudotyped particles. Using a yeast two-hybrid screening strategy, the inventors have identified cellular factors that interact with the SARS-CoV's E, S and M proteins, in particular, ezrin (ERM protein) and PALS1 (PDZ-domain containing protein) for interaction with S and E proteins, respectively.…”
Section: Inhibitors With Unknown Targetsmentioning
confidence: 99%
“…A WO patent [78] and a Canadian patent [79] as well as their paper [80] published by inventors from Hong-Kong Pasteur Research Center, China, relates to the identification and/ or use of anti-CoV molecules that inhibit or disrupt viral protein-cellular protein interactions, important or essential in the viral life cycle of a CoV, for example, a method for identifying inhibitors of early stages of SARS-CoV replication cycle by using lentiviral Spike pseudotyped particles. Using a yeast two-hybrid screening strategy, the inventors have identified cellular factors that interact with the SARS-CoV's E, S and M proteins, in particular, ezrin (ERM protein) and PALS1 (PDZ-domain containing protein) for interaction with S and E proteins, respectively.…”
Section: Inhibitors With Unknown Targetsmentioning
confidence: 99%
“…In particular, this report identifi ed nsp1 interaction with several members of immunophilin and calcipressin families, which led to demonstrate SARS sensitivity to cyclosporin A. More recently, another Y2H screen performed with the C-terminal domain of the spike glycoprotein (S) identifi ed Ezrin as a binding partner and a restriction factor of SARS-CoV [ 24 ]. Since 2005, a technological platform is up and running in our laboratory at Institut Pasteur, and dedicated to virus-host interaction mapping for a large panel of RNA viruses.…”
Section: Immunofl Uorescence Analysismentioning
confidence: 92%
“…In particular, this report identifi ed nsp1 interaction with several members of immunophilin and calcipressin families, which led to demonstrate SARS sensitivity to cyclosporin A. More recently, another Y2H screen performed with the C-terminal domain of the spike glycoprotein (S) identifi ed Ezrin as a binding partner and a restriction factor of SARS-CoV [ 24 ].…”
Section: Introductionmentioning
confidence: 92%